? BIOINFORMATICS SHARED RESOURCE The Bioinformatics Shared Resource (BSR) provides Cancer Center (CC) members with access to state-of- the-art technology for analysis of high dimensional datasets involving next-generation sequencing, microarray, proteome and metabolome platforms, as well as integration of multi-omics results. The BSR develops algorithms, computational tools and databases ideally suited for the quantitative analysis of a wide variety of experimental questions in cancer research. Services offered by the BSR include: (i) statistical analyses and computational modeling; (ii) development of advanced bioinformatics tools for integrative cancer biology; and (iii) data management. The BSR has undergone significant growth in expertise and capabilities during the last Cancer Center Support Grant (CCSG) budget cycle. This was in response to the large thematic faculty recruitment in the CC, the expansion of computational-intensive research themes (cancer metabolism, phenotype profiling) and the growing need for high-dimensional data analysis across multiple technologies. Rehman Qureshi, Ph.D., Harsh Dweep, Ph.D. and Hideki Tanizawa, Ph.D. were recruited to the BSR staff during the last CCSG budget cycle to expand computational expertise; Wen-Hwai Horng, M.S. led the synergistic integration of system administration with a reorganized Wistar Information Technology (IT) Department, and a data analysis pipeline was developed synergistically with the Genomics, Proteomics and Molecular Screening Shared Resources to ensure seamless flow of data and appropriate quality control, feedback and troubleshooting. BSR staff and the Scientific Director are located within dry laboratory space in the Center for Systems and Computational Biology, next to Biostatistics faculty and post-doctoral fellows with strong interests in computational biology. The central location of the BSR facilitates scientific exchange and collaborations, thereby increasing the overall level of analytic approaches and quality of results. During the last CCSG budget cycle, CC members from all three Programs have extensively utilized BSR services contributing to a broad portfolio of cancer-related publications and grant awards. As an additional measure of the critical impact of its services, the BSR engages in productive collaborations with neighboring academic Institutions and Cancer Centers including the University of Pennsylvania, Children?s Hospital of Philadelphia (CHOP), Fox Chase Cancer Center, Lankenau Institute for Medical Research, and Drexel University. The expansion and refinement of bioinformatics tools of the last CCSG budget cycle have ideally positioned the BSR for state-of- the-art management of complex datasets and emerging technologies in sync with the recent CC expansion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-50
Application #
9701528
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
50
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Duperret, Elizabeth K; Liu, Shujing; Paik, Megan et al. (2018) A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clin Cancer Res 24:6015-6027

Showing the most recent 10 out of 741 publications